Dublin, June 28, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Castration-Resistant Prostate Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ResearchAndMarkets.com's offering.
The 7 major metastatic castration-resistant prostate cancer markets are expected to exhibit a CAGR of 5.44% during 2023-2034.
This report provides an exhaustive analysis of the metastatic castration-resistant prostate cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc.
The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for metastatic castration-resistant prostate cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report.
Key Highlights
- The rising cases of hormonal imbalances, which allow cancer to survive and even thrive in low-androgen environments, are primarily driving the metastatic castration-resistant prostate cancer market.
- In addition to this, the escalating prevalence of genetic mutations that impair the cell's ability to repair DNA damage, leading to the development of aggressive tumors, is also creating a positive outlook for the market.
- Moreover, the widespread adoption of stereotactic body radiation therapy, since it can deliver precise doses of energy beams to targeted tumor sites, thereby providing localized treatment, is further bolstering the market growth.
- Apart from this, the inflating application of immune checkpoint inhibitors, like pembrolizumab and nivolumab, to stimulate the defense system's response against cancerous cells and improve the quality of life in patients is acting as another significant growth-inducing factor.
- Additionally, the emerging popularity of targeted therapies, such as enzalutamide, abiraterone acetate, apalutamide, etc., that can block specific pathways involved in the proliferation and progression of tumor growth is expected to drive the metastatic castration-resistant prostate cancer market during the forecast period.
Time Period of the Study
- Base Year: 2023
- Historical Period: 2018-2023
- Market Forecast: 2024-2034
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the metastatic castration-resistant prostate cancer market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the metastatic castration-resistant prostate cancer market
Competitive Landscape
This report also provides a detailed analysis of the current metastatic castration-resistant prostate cancer marketed drugs and late-stage pipeline drugs:
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
For more information about this report visit https://www.researchandmarkets.com/r/mjla5g
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
